Introduction

Mesenchymal tumors of the prostate are seen relatively rare in comparison with epithelial tumors and constitute less than 1% of all tumors (1). Despite they are seen rarely, there are great numbers of lesions in the differential diagnosis of mesenchymal tumors. Since mesenchymal tumors of the prostate are seen rarely, pathologists have very limited experience in this regard. Additionally, mesenchymal tumors show morphologically significant overlap with epithelial tumors causing problem particularly in the differential diagnosis of spindle cell mesenchymal tumors and they frequently require ancillary methods for accurate diagnosis.

Patients are mostly middle-aged and older and they generally present to hospital with symptoms of nonspecific urinary system obstruction. Besides, hematuria and rectal distension may be the admission symptoms as well. Prostate abnormality can be observed during examination, and increased serum prostate-specific antigen can be detected. Any of these symptoms and findings may not be a specific clinical finding of mesenchymal tumors. Imaging methods are not always reliable to identify the nature of the lesion. Well-circumscribed lesions may not always be benign, for example some prostatic sarcomas show well circumscribed growth pattern. Infiltrative-circumscribed lesions are not always malignant tumors; some mesenchymal tumors, such as inflammatory myofibroblastic tumors (IMTs), are infiltrative-circumscribed in spite of benign nature.

Biopsy is necessary for diagnosis. However, diagnosis is difficult in cases where a very limited part of the tumor is sampled at transurethral resection or needle biopsy. Stromal tumors of uncertain malignant potential (STUMP) containing, especially, mesenchymal as well as epithelial components, may not be noticed and they may be diagnosed as benign prostate tissue or tumors containing pure spindle cell components can be mixed with stromal hyperplasia. There are numerous subtypes of mesenchymal tumors and the most commonly used categorization is the World Health Organization classification. This classification is summarized in Table 1 (2). Morphological and immunohistochemical characteristics of mesenchymal tumors of the prostate are given in Table 2 and 3.

Prostatic Stromal Tumors

Since histological patterns of tumors originating from the specialized prostatic stroma show wide spectrum, these tumors are classified into two different categories as prostatic STUMP and stromal sarcoma for making predictions about biological behavior and for treatment planning (3). Less than 100 cases of STUMP, which has been described by several names, such as atypical stromal hyperplasia, cystic epithelial-stromal tumor and phylloides, has been reported in the literature (3,4,5,6). STUMPs
have been reported to occur between the ages of 27 and 83 years with a peak incidence between 6th and 7th decades. They can be in the white, tan, solid or solid-cystic pattern (Figure 1) and up to 15 cm in size. STUMPs have been classified into four histologic patterns. The first pattern contains hypercellular stroma showing degenerative atypia with benign glands; the second pattern contains bland, fusiform stromal cells with eosinophilic cytoplasm with benign glands; the third pattern contains benign phylloides tumor-like hypercellular stroma with cytologically atypical/non-atypical benign glands and; the fourth pattern contains bland stromal cells in myxoid stroma without prostate glands (Figure 2). Recently, Sadimin and Epstein (7) described a novel round cell pattern. It shows CD34 (+), vimentin (+), progesterone (+), S100 (-) and C-kit (-) staining patterns, immunohistochemically. A large proportion of STUMPs has atypia and may imitate malignant lesions such as stromal sarcoma. However, absence of atypical mitosis and presence of degenerative appearance of atypical nuclei with benign prostate glands help distinguish it from malignant tumors. STUMP is typically indolent, and generally cured with complete resection (3,8). However, as sarcomatoid differentiation may occur rarely, close follow-up is required in cases where complete resection is not possible (1,3).

Prostatic stromal sarcoma (PSS) is a rare malignant neoplasm originating from specialized stromal prostatic cells. Less than 40 cases of PSS have been reported in the literature (1). PSS has been reported to occur between the ages of 25 and 86 years. Half of the cases were under 50 years of age. PSS may arise de novo or it may develop from a previous STUMP (5). Macroscopically, PSS is a tan-white, solid, fleshy tumor 2-18

![Figure 1](image1.png) **Figure 1.** White-tan and solid-cystic pattern, well circumscribed stromal tumors of uncertain malignant potential

![Figure 2](image2.png) **Figure 2.** High magnification of a stromal tumors of uncertain malignant potential shows degenerative-appearing spindle cells in hypercellular stroma without glands

<table>
<thead>
<tr>
<th>Table 2. Morphologic features of mesenchymal tumors of the prostate</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Morphological characteristic</strong></td>
</tr>
<tr>
<td>Four patterns: (1) Hypercellular stroma showing degenerative atypia with benign glands, (2) bland fusiform-shaped stromal cells with eosinophilic cytoplasm with benign glands, (3) benign phylloides tumor-like hypercellular stroma with cytologic atypical/non-atypical benign glands, (4) bland stromal cells in myxoid stroma without prostate glands</td>
</tr>
</tbody>
</table>

cm in size. Microscopically, it is similar to STUMP. Unlike STUMP, it exhibits marked increased cellularity, stromal cellular atypia, mitosis (which may be in atypical forms), and necrosis. The most common patterns are storiform, epithelioid, fibro sarcomatous, or patternless pattern. Less frequently, it consists of malignant phylloid tumor-like hypercellular stroma and leaf-like glands. Its PSS storiform cell component consists of one or more of the followings: hypercellularity, cytologic atypia, mitotic figure and necrosis. It shows CD34 (+), vimentin (+), progesterone (+), S100 (-) and C-kit (-) staining pattern, immunohistochemically. In addition, PSSs are divided into two subgroups as low- and high-grade. High-grade tumors include moderate-evident cytologic atypia, hypercellularity, increased mitotic activity and necrosis. Low-grade PSSs are local invasive and high-grade ones metastasize mostly to the lung and bone, and usually require complete resection and adjuvant therapy (5).

**Leiomyoma**

Leiomyoma is seen rarely and less than 100 cases have been reported in the literature (9). Microscopically, they are non-atypical or less atypical tumors consisting of well-circumscribed crossing fascicular structures and having no mitotic activity. They are between 1 and 12 cm in size. Immunohistochemically, It differs from STUMP and gastrointestinal stromal tumor (GIST) by its smooth muscle actin (SMA) (+), desmin (+), C-kit (-) and CD34 (-) staining pattern.

**Leiomyosarcoma**

It is the most common sarcoma in the prostate in adults in the 5th to 8th decades of life (2,9). It is seen as poor-circumscribed infiltrative nodules between 1 and 25 cm in diameter. They are tumors composed of crossing-fascicular structures and they show mitosis, cytologic atypia and necrosis at high level. Immunohistochemically, it differs from other high-grade sarcomas by its SMA (+), desmin (+), h-caldesmon (+) S100 (-), C-kit (-) and CD34 (-) staining pattern. The clinical course of leiomyosarcomas is characterized by multiple recurrences and pulmonary metastasis. Most patients die within 3-4 years of diagnosis (2).

**Gastrointestinal Stromal Tumor**

GISTs develop from the rectum or perirectal region and keep the prostate as a secondary site by infiltrating or compressing. Although GISTs occur in the gastrointestinal system, small numbers of prostatic GISTs have been reported in the literature (10,11). They contain perinuclear vacuoles in fascicular growth pattern and consist of storiform and epithelioid cells. Immunohistochemically, they differ from other mesenchymal tumors by CD34 (+), C-kit (+), discovered on GIST-1 (+), desmin (+/-), SMA (+/-), CD31 (-) and S100 (-) staining. Since their response to imatinib treatment is very good, correct diagnosis is very important.

**Rhabdomyosarcoma**

It is the most common soft tissue sarcoma in children. It has been reported very rarely in adulthood (2,12). They are tumors composed of small round cells with scant cytoplasm and variable numbers of eosinophilic small round cells, and elongated cells with occasionally variable eosinophilic cytoplasm on a frequent myxoid zone. Immunohistochemically, they differ from other tumors by myogenic differentiation 1 (+), myogenin (+), desmin (+) myoglobin (+), muscle specific actin (+), keratin (-) and terminal deoxynucleotidyl transferase (-) staining pattern. They respond well to multimodality treatment in childhood, but metastasis occurs even if complete resection is performed. Approximately half of adults die within 2 years due to the disease (12).

**Inflammatory Myofibroblastic Tumor**

IMTs have been described by several names such as post-operative spindle cell nodules in the literature (13). Morphology, molecular features and clinical behavior of the lesions, which develop as de novo or after a lower genitourinary tract procedure, are similar. IMT has been reported to affect adults between the ages of 42 and 67 years. Most of them are smaller
than 1 cm in size. They are tumors composed of uniform, reactive myofibroblasts on a loose zone with variable level of inflammation and extravasation of red blood cells. It shows vimentin (+), anaplastic lymphoma kinase-1 (+), calponin (+/−), SMA (+/−), CD34 (-), C-kit (-), keratin (-) and S100 (-) staining patterns. Although many cases of incomplete resections have been reported, they behave in a benign fashion and there is one reported case of metastasis in the literature (8).

**Solitary Fibrous Tumor**

Solitary fibrous tumor (SFT) is a rare storiform cell neoplasia, which is seen on the pleura and peritoneum. The first reported case of SFT involving the prostate was one of 5 tumors in the lower urinary tract in 2000 year (14). Up to now, 20 cases of SFT involving the prostate have been reported (8). It has been reported that patients with prostatic SFT were between the ages of 21 and 75 years and the lesions were measured 2-14 cm in size. Microscopically, it is composed of storiform cells that do not form any pattern. The classical histological feature of these tumors is the “irregular order” appearance. It also contains thick collagen bands and hyalinizing vessels in the form of distinctly branched, deer horn. Immunohistochemically, it differs from other mesenchymal tumors by its CD34 (+), signal transduction and activation of transcription 6 (+), aldehyde dehydrogenase 1 (+), desmin (-), SMA (-), CD31 (-), S100 (-) and C-kit (-) staining pattern (15). Although most of the SFT show benign features, some of these tumors have malignant characters which show high mitotic activity (greater than 4/10 high power fields), mild and evident nuclear pleomorphism, increased cellularity, necrotic or hemorrhagic areas. Four cases have been reported so far in the literature (16,17).

**Other Lesions**

Mesenchymal tumors which are not specific for prostate such as angiosarcoma, synovial sarcoma, osteosarcoma, undifferentiated pleomorphic sarcoma, haemangiomia, granular cell tumor and neural tumors have been reported as rare cases (2).

**Conclusion**

Despite the fact that mesenchymal tumors of the prostate constitute less than 1% of all tumors, their differential diagnosis is difficult and includes a broad spectrum of conditions. For this reason, it is important that clinical and radiological findings are reported to pathologists and adequate biopsy specimens are obtained. In spite of all these, the differential diagnosis of mesenchymal tumors may be problematic and ancillary methods may be needed for accurate diagnosis.

**Acknowledgements**

Special thanks to Prof. Dr. Kutsal Yörükoğlu for redaction and the figures.

**Keywords:** Prostate, Mesenchymal tumor, Differential diagnosis

**Anahtar Kelimeler:** Prostat, Mezenkimal tümör, Ayırıcı tanı

**Ethics**

**Peer-review:** Externally peer-reviewed.

**Financial Disclosure:** The author declared that this study received no financial support.

**References**